Oruka Reports 61% Complete Skin Clearance at Week 16 in Trial
Oruka Therapeutics said 61% of patients receiving high-dose ORKA-001 achieved complete skin clearance at Week 16 in its Phase 2b psoriasis trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.